NASDAQ:IRON Disc Medicine Q2 2026 Earnings Report $65.87 +0.95 (+1.46%) Closing price 09/29/2026 04:00 PM EasternExtended Trading$66.54 +0.66 (+1.01%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Disc Medicine EPS ResultsActual EPS-$1.54Consensus EPS -$1.71Beat/MissBeat by +$0.17One Year Ago EPSN/ADisc Medicine Revenue ResultsActual RevenueN/AExpected Revenue$1.00 millionBeat/MissN/AYoY Revenue GrowthN/ADisc Medicine Announcement DetailsQuarterQ2 2026Date7/30/2026TimeBefore Market OpensConference Call DateThursday, July 30, 2026Conference Call Time8:30AM ETUpcoming EarningsDisc Medicine's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, October 30, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Disc Medicine Earnings HeadlinesDisc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 28 at 3:02 PM | globenewswire.comROSEN, A LONGSTANDING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONSeptember 27 at 3:11 PM | markets.businessinsider.comThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story.September 30 at 1:00 AM | Stansberry Research (Ad)Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONSeptember 26, 2026 | prnewswire.comDisc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 25, 2026 | globenewswire.comDisc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 22, 2026 | globenewswire.comSee More Disc Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Disc Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Disc Medicine and other key companies, straight to your email. Email Address About Disc MedicineDisc Medicine (NASDAQ:IRON) (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s research centers on disorders involving red blood cell production, iron metabolism and related biological pathways, with the goal of addressing conditions that often have limited treatment options. Disc Medicine’s lead product candidate is bitopertin, an oral small-molecule inhibitor of glycine transporter 1. The company is evaluating bitopertin in diseases including erythropoietic protoporphyria, a rare disorder characterized by abnormal accumulation of protoporphyrin that can cause severe sensitivity to sunlight. Its pipeline also includes DISC-0974, an investigational antibody designed to target hemojuvelin and regulate hepcidin, a hormone involved in iron metabolism, for potential use in anemia associated with chronic disease and other hematologic conditions. Founded in 2017, Disc Medicine is headquartered in Waltham, Massachusetts. The company’s programs are in clinical development and are being evaluated through studies conducted in the United States and other regions. Disc Medicine is led by John Quisel, who serves as president and chief executive officer.View Disc Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
